Evaluation of heart rate variability using 24-hour Holter electrocardiography in hypertensive patients

Rerdin Julario MD | Eka Prasetya Budi Mulia MD | Dita Aulia Rachmi MD | Maya Qurota A’yun MD | Imanita Septianda MD | Ivana Purnama Dewi MD | Rahima Ratna Juwita MD | Budi Baktijasa Dharmadjati MD

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia

Correspondence
Rerdin Julario, MD, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Hospital, Jalan Mayjen Prof. Dr. Moestopo No.6-8, Surabaya 60286, Indonesia.
Email: dr.rerdinjulario@gmail.com

Abstract
Background: Hypertension (HTN) remains a serious risk factor for cardiovascular mortality across the world. Hypertensive state has been shown to be associated with autonomic nervous function. This study aimed to explore the association between autonomic nervous impairment assessed by heart rate variability (HRV) and HTN.

Methods: A total of 52 hypertensive and 55 non-hypertensive patients were consecutively studied using 24-hour Holter. The hypertensive patients were grouped into controlled blood pressure (BP) and uncontrolled BP. This study compared HRV in non-hypertensive and hypertensive patients; and hypertensive patients with controlled and uncontrolled BP. HRV parameters include time and frequency domain.

Results: Mean age for hypertensive and non-hypertensive patients were 53.58 ± 14.31 and 44.89 ± 16.63 years old, respectively. Median (IQR) SDNN for hypertensive and non-hypertensive group were 109.00 (90.00-145.00) and 129.00 (107.00-169.00), respectively. SDNN, ASDNN, rMSSD, pNN50, BB50, VLF, and HF values were significantly lower in the hypertensive group compared to non-hypertensive group (all \( P < .05 \)). A multiple regression analysis showed that HRV parameters: SDANN, ASDNN, rMSSD, and LF values were independent risk factors of HTN. SDNN, SDANN, ASDNN, VLF, LF, and HF values were significantly lower in the hypertensive group compared to non-hypertensive group (all \( P < .05 \)). A multiple regression analysis showed that HRV parameters: SDNN, SDANN, rMSSD, and HF values were independent risk factors of uncontrolled BP in hypertensive patients.

Conclusions: Our study showed that cardiac autonomic nervous impairment, as demonstrated by reduced HRV, is significantly associated with HTN. Decreased HRV was more evident in uncontrolled BP than in controlled BP group.

Keywords
autonomic nervous system, blood pressure, heart rate variability, Holter, hypertension
1 | INTRODUCTION

Hypertension (HTN) remains a serious risk factor for cardiovascular mortality across the world. The asymptomatic nature of HTN may hinder diagnosis and prompt initiation of appropriate therapies. Essential hypertensive disorders can be identified not only by reduced parasympathetic tones but also by a severe sympathetic overdrive, resulting in an increase in resting heart rate values. Another literature summarises sympathetic dysregulation in the differentiation risk in stages of HTN (mild, moderate, severe), form of hypertension in young, middle-aged, and elderly, white-coat HTN, masked HTN, and gestational HTN. Heart rate variability (HRV) influences the autonomic control of cardiac function. HRV reflects the autonomic nervous system response to external stimuli. Abnormal HRV represented autonomous imbalance and was associated with worse cardiovascular outcome.

One of the major studies that found reduced HRV in males and females with systemic HTN was the Framingham Heart Study. This study also found that LF (low frequency) power of HRV was correlated with new-onset HTN in men. The assessment of HRV using 24-hour Holter Electrocardiography (ECG) is a simple and reliable tool to assess autonomic imbalance in HTN patients. Analyzing HRV may be beneficial in improving our understanding of underlying pathophysiology, optimizing treatment modalities for hypertensive patients subsets with signs of autonomic impairment, and predicting future major adverse cardiovascular events (MACE) in patients at risk. This study aimed to explore the association between HRV in non-hypertensive and hypertensive patients and between controlled and uncontrolled BP of hypertensive patients.

2 | METHODS

2.1 | Study design and study setting

This was an observational study using a retrospective cross-sectional design. This study was held at Cardiac Center—Dr Soetomo General Hospital, Surabaya, Indonesia.

2.2 | Study population

A total of 52 patients with HTN or hypertensive heart disease and 55 patients without HTN or hypertensive heart disease as controls in 24-hour Holter ECG Registry Data from April 2019 to March 2020 were chosen and included in this study. All subjects are in the ages between 15 and 80 years old. All hypertensive patients received antihypertensive medication. Patients with hypertension were grouped into controlled blood pressure (BP) (n = 18), and uncontrolled BP (n = 34). BP of each subjects were measured right before Holter recording at outpatient clinic. Patients with second or third-degree atrioventricular block, atrial fibrillation, atrial flutter, sinus arrest, pacemaker implantation, pregnant, and missing required data were excluded.

Blood pressure was recorded with validated digital BP device Omron M3 (HEM-7200-E) in sitting posture after five-minutes of rest. The diagnosing criteria of HTN were BP ≥140/90 mm Hg (according to Joint National Committee/JNC VII classification). Subject with BP ranging from 100-139/60-89 mm Hg was recruited into non-hypertensive group. Subject with BP ≥140/90 mm Hg or self-reported use of anti-hypertensive drugs during the 2 weeks prior to the clinical examination was recruited into hypertensive group. Subject with self-reported use of anti-hypertensive drugs during the 2 weeks prior to the clinical examination and BP ≥140/90 mm Hg was recruited into uncontrolled BP group.

2.3 | Ethical clearance

Institutional committee of research and ethics of Dr Soetomo General Academic Hospital gave ethical clearance and approved the study (Ref: 1822/KEPK/II/2020).

2.4 | Data collection

All participants were subjected to 24-hour Holter ECG monitoring (MARS PC Holter Monitoring and Review System software and SEER Light Digital Holter Recorder; GE). Each patient was given a detailed explanation of how the test was done and how to handle the recorder. Holter ECG was placed in the patient’s waist, and the electrode leads were placed appropriately on the chest. The patients were instructed to go home, recommence normal daily activities, and return to hospital after 24 hours.

2.5 | HRV analysis

Data analysis of quantitative HRV was carried out based on the guidelines of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. HRV parameters, including time domain and frequency domain, were obtained from 24-hour Holter monitoring. We used seven time-domain variables: average of all intervals between normal beats excluding ectopy or noise intervals (mean NN), standard deviation of intervals of all normal beat (SDNN), standard deviation of five-minute mean R-R interval (SDANN), mean of five-minute standard deviations of intervals (ASDNN), root mean square of the difference of successive R-R intervals (rMSSD), percentage of intervals that are more than 50 ms different from the previous interval (pNN50), count of intervals that are more than 50 ms different from the previous interval (BB50). Four frequency domain variables included very low frequency (VLF: 0.0033-0.04 Hz), low frequency (LF: 0.04-0.15 Hz), high frequency (HF:0.15-0.4 Hz), and low-frequency/
2.6 | Statistical analysis

The statistical analysis was done using SPSS version 25 software for Windows (IBM Corp). Descriptive statistics of continuous data were given as mean (standard deviations [SD]) or median (interquartile range [IQR]) depend on data distribution, while categorical data were given as n (%). Data distribution was tested using One-Sample Kolmogorov–Smirnov test. Continuous variables with normal distribution were analyzed by an independent T-test. Non-normal distributed data were analyzed by Mann–Whitney U test. Chi-square test was used to compare categorical variables. The HRV parameters as risk factors for HTN and uncontrolled BP of hypertensive patients were determined by multivariate logistic regression model after adjusting for age, sex, body mass index (BMI), amiodarone use, beta-blockers use, of angiotensin-converting enzyme inhibitors/ angiotensin II receptor blockers (ACE-i/ARB) use, calcium channel blocker (CCB) use, and diuretic use. Receiver Operating Characteristic (ROC) curve was used to determine the optimal cut-off of HRV parameters. P values less than .05 were considered statistically significant.

3 | RESULTS

3.1 | Baseline characteristics of study population

Characteristics of study population are summarized in Table 1. The study involved a total of 107 patients: 52 hypertensive patients (28 males) and 55 non-hypertensive patients (24 males). There was no difference in distribution of sex between two groups. Mean age for hypertensive and non-hypertensive patients were 53.58 ± 14.31 and 44.89 ± 16.63 years old, respectively. Mean heart rate for hypertensive and non-hypertensive patients were 76.67 ± 14.03 and 74.27 ± 12.49 bpm, respectively. Diabetes mellitus (DM) was found in 3.8% of hypertensive patients and 3.6% of non-hypertensive patients. History of arrhythmia became the most common comorbidity in both groups: 50.0% in hypertensive patients and 81.8% in non-hypertensive patients. The use of ACE-i/ARB and CCB was higher in hypertensive group, while the use of anti-arrhythmic drug amiodarone was higher in non-hypertensive group.

Table 2 showed baseline characteristics of hypertensive population with controlled and uncontrolled BP. The mean age for controlled and uncontrolled BP patients were 50.06 ± 13.97 and 55.44 ± 14.34 years old, respectively. Comorbidities and medications were evently distributed between two groups.

| Variables                  | HTN (N = 52) | Non-HTN (N = 55) | P    |
|----------------------------|--------------|------------------|------|
| Age (y)                    | 53.58 ± 14.31| 44.89 ± 16.63    | .005 |
| Sex male (n, %)            | 28 (53.8%)   | 24 (43.6%)       | .291 |
| BMI (kg/m²)                | 26.70 ± 3.63 | 25.76 ± 3.37     | .165 |
| Heart rate (bpm)           | 76.67 ± 14.03| 74.27 ± 12.49    | .351 |
| SBP (mm Hg)                | 140.00 (120.00-157.25) | 120.00 (110.00-125.00) | <.001 |
| DBP (mm Hg)                | 90.00 (80.00-100.00) | 80.00 (75.00-81.00) | <.001 |
| Stroke (n, %)              | 1 (1.9%)     | 0 (0.0%)         | .486 |
| History of arrhythmia (n, %)| 26 (50.0%)   | 45 (81.8%)       | <.001 |
| DM (n, %)                  | 2 (3.8%)     | 2 (3.6%)         | .954 |
| VHD (n, %)                 | 2 (3.8%)     | 0 (0.0%)         | .234 |
| CAD (n, %)                 | 12 (23.1%)   | 5 (9.1%)         | .048 |
| CHD (n, %)                 | 0 (0.0%)     | 3 (5.5%)         | .244 |
| Medication:                |              |                  |      |
| Beta blocker (n, %)        | 34 (65.4%)   | 30 (54.5%)       | .253 |
| Amiodaron (n, %)           | 5 (9.6%)     | 12 (21.8%)       | .084 |
| CCB (n, %)                 | 14 (26.9%)   | 5 (9.1%)         | .016 |
| ACE-i/ARB (n, %)           | 28 (53.8%)   | 12 (21.8%)       | .001 |
| Diuretic (n, %)            | 8 (15.4%)    | 4 (7.3%)         | .228 |

Note: Data are presented as mean ± SD, median (IQR), n (%).
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; VHD, valvular heart disease.
### TABLE 2 Baseline characteristics of hypertensive population with controlled and uncontrolled BP

| Variables | Uncontrolled BP (N = 34) | Controlled BP (N = 18) | P   |
|-----------|--------------------------|------------------------|-----|
| Age (y)   | 55.44 ± 14.34            | 50.06 ± 13.97          | .200|
| Sex male (n, %) | 20 (58.8%)       | 8 (44.4%)              | .322|
| BMI (kg/m²) | 27.41 ± 3.24            | 25.38 ± 4.04           | .054|
| Heart rate (bpm) | 77.26 ± 12.25  | 75.56 ± 17.24          | .712|
| SBP (mm Hg) | 151.50 (140.00-165.00) | 115.00 (110.00-120.00) | <.001|
| DBP (mm Hg) | 95.00 (90.00-100.00)    | 80.00 (73.75-80.00)    | <.001|
| Stroke (n, %) | 1 (2.9%)              | 0 (0.0%)               | .463|
| History of arrhythmia (n, %) | 19 (55.9%)     | 7 (38.9%)              | .244|
| DM (n, %) | 1 (2.9%)                 | 1 (5.6%)               | .641|
| VHD (n, %) | 0 (0.0%)                 | 2 (11.1%)              | .115|
| CAD (n, %) | 8 (23.5%)                | 4 (22.4%)              | .915|
| CHD (n, %) | 0 (0.0%)                 | 0 (0.0%)               | -   |
| Medication: |                      |                        |     |
| Beta blocker (n, %) | 22 (64.7%)    | 12 (66.7%)             | .888|
| Amiodaron (n, %) | 4 (11.8%)        | 1 (5.6%)               | .648|
| CCB (n, %) | 11 (32.4%)              | 3 (16.7%)              | .329|
| ACE-i/ARB (n, %) | 19 (55.9%)     | 9 (50.0%)              | .686|
| Diuretic (n, %) | 5 (14.7)          | 3 (16.7%)              | .852|

Note: Data are presented as mean ± SD, median (IQR), n (%). Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; VHD, valvular heart disease.

### 3.2 Heart rate variability analysis in hypertensive and non-hypertensive patients

Table 3 shows the correlation between HRV parameters obtained from 24-hour Holter ECG recordings and HTN. Median (IQR) SDNN for hypertensive and non-hypertensive group were 109.00 (90.00-145.00) and 129.00 (107.00-169.00), respectively. SDNN, ASDNN, rMSSD, pNN50, BB50, VLF, and HF values were significantly lower in the hypertensive group compared to non-hypertensive group (all P < .05). Based on the shortest distance on the ROC curve (corresponding to the largest sum of sensitivity and specificity) (Figure 1, Table S1), optimal cut-off for SDNN was 111.5 ms (sensitivity 71% and specificity 52%, area under the curve/AUC 0.626), ASDNN was 39.5 ms (sensitivity 78% and specificity 43%, AUC 0.631), rMSSD was 20.5 ms (sensitivity 84% and specificity 43%, AUC 0.621), pNN50 was 36.5% (sensitivity 73% and specificity 52%, AUC 0.646), BB50 was 2913.50 beats (sensitivity 78% and specificity 48%, AUC 0.668), VLF was 23.57 ms (sensitivity 75% and specificity 46%, AUC 0.619), and HF was 9.07 ms (sensitivity 71% and specificity 44%, AUC 0.634).

### 3.3 Multivariate adjusted factors related to HTN

Multiple regression analysis showed that HRV parameters: SDANN, ASDNN, rMSSD, and LF values were independent risk factors of HTN after adjusting for age, sex, BMI, amiodarone use, beta-blockers use, ACE-i/ARB use, CCB use, and diuretic use (Table 4).

### 3.4 Heart rate variability analysis in uncontrolled and controlled blood pressure in hypertensive patients

Table 5 shows the correlation between HRV parameters obtained from 24-hour Holter ECG recordings and the control status of BP in hypertensive group. Median (IQR) SDNN for uncontrolled and controlled BP were 105.00 (89.00-131.00) and 128.50 (99.00-197.00), respectively. SDNN, SDANN, ASDNN, VLF, LF, and HF values were significantly lower in the uncontrolled BP group compared to controlled BP group (all P < .05). Based on the shortest distance on the ROC curve (corresponding to the largest sum of sensitivity and specificity) (Figure 2, Table S2), optimal cut-off for SDNN was 96.50 ms (sensitivity 83% and specificity 44%, AUC 0.672), SDANN was 83.50 ms (sensitivity 89% and specificity 44%, AUC 0.673), ASDNN was 51.50 ms (sensitivity 67% and specificity 73%, AUC 0.685), VLF was 30.92 ms (sensitivity 67% and specificity 85%, AUC 0.698), LF was 23.03 ms (sensitivity 61% and specificity 91%, AUC 0.735), and HF was 7.71 ms (sensitivity 89% and specificity 44%, AUC 0.680).

### 3.5 Multivariate adjusted factors related to uncontrolled blood pressure of hypertensive patients

Multiple regression analysis showed that HRV parameters: SDNN, SDANN, and rMSSD values were independent risk factors of uncontrolled blood pressure in hypertensive patients after adjusting for age, sex, BMI, amiodarone use, beta-blockers use, ACE-i/ARB use, CCB use, and diuretic use (Table 6).

### 4 DISCUSSION

This study showed that decreased HRV level has significant association with increased BP. This significance is independent in every confounder tested by both frequency and time domain. These results are in-line with previous findings for Asian population which showed that impaired autonomic nervous function in hypertensive patients is strongly associated with uncontrolled BP.7-12 Our study
showed that hypertensive patients had significantly lower SDNN (reflecting vagal function)\(^{10}\) as well as meanNN, ASDNN, rMSSD (reflecting vagal function),\(^{7}\) pNN50 (reflecting vagal function),\(^{7}\) and BB50, VLF (reflecting vagal function), HF (reflecting vagal function),\(^{7}\) and LF/HF ratio (reflecting sympathovagal balance)\(^{12}\) compared to non-hypertensive patients. SDNN, SDANN, ASDNN, VLF, LF (reflecting sympathovagal balance),\(^{7}\) and HF were significantly lower in hypertensive group with uncontrolled BP. Our result revealed that hypertensive patient had greater impairment in cardiac autonomic nervous activity than non-hypertensive patients. More severe impairment was showed in hypertensive group with uncontrolled BP.

Multiple studies investigating the relationship between HRV and HTN were done in Asian population. Khoicybekov et al used five-minute ECG recording to calculate non-linear indices D2, K2, and lagged Poincaré plot. The data reported that heart rhythm variability in HTN group was less in variability than in non-HTN group.

**TABLE 3** Comparison of heart rate variability parameters in hypertensive and non-hypertensive patients

| HRV parameters | HTN (N = 52) | Non-HTN (N = 55) | P |
|----------------|--------------|------------------|---|
| **Time domain:** |              |                  |   |
| mean NN (ms)   | 746.00 (698.25-853.00) | 801.00 (730.00-884.00) | .091 |
| SDNN (ms)      | 109.00 (90.00-145.00) | 129.00 (107.00-169.00) | .024 |
| SDANN (ms)     | 101.00 (79.00-144.75) | 119.00 (90.00-153.00) | .109 |
| ASDNN (ms)     | 44.00 (34.25-66.50)   | 54.00 (40.00-81.00)   | .020 |
| rMSSD (ms)     | 27.50 (19.00-34.50)   | 30.00 (25.00-48.00)   | .030 |
| pNN50 (%)      | 29.00 (9.25-90.75)    | 75.00 (27.00-194.00)  | .009 |
| BB50 (beats)   | 3627.00 (1330.50-8270.50) | 6825.00 (3122.00-15 530.00) | .003 |
| **Frequency domain:** |              |                  |   |
| VLF (ms)       | 24.37 (19.31-36.18)   | 29.78 (22.63-44.76)   | .034 |
| LF (ms)        | 15.72 (11.90-23.57)   | 19.99 (13.91-35.44)   | .053 |
| HF (ms)        | 10.44 (6.47-13.82)    | 12.94 (8.75-19.14)    | .017 |
| LF/HF ratio    | 1.62 (1.35-2.33)      | 1.49 (1.25-2.12)      | .336 |

Note: Data are presented as median (IQR).
Abbreviations: ASDNN, mean of five-minute standard deviations of intervals; BB50, count of intervals that are more than 50 ms different from the previous interval; HF, high-frequency power; HTN, hypertension; HRV, heart rate variability; LF, low-frequency power; mean NN, average of all intervals between normal beats excluding ectopy or noise intervals; pNN50, percentage of intervals that are more than 50 ms different from the previous interval; rMSSD, root mean square of the difference of successive R-R intervals; SDANN, standard deviation of five-minute mean R-R interval; SDNN, standard deviation of intervals of all normal beat.
A similar study in India involving 30 hypertensive patients and 30 non-hypertensive patients showed significantly reduced HFnu, SDNN, rMSSD, pNN50, and significantly increased LFnu and LF-HF ratio in hypertensive individuals. The study also used five-minutes of ECG recording. A study from Japan showed parasympathetic nervous system activity impairment were associated with increased ambulatory mean arterial pressure in the morning. Another study suggested that HRV reflects diastolic BP better than systolic BP levels and that alcohol intake strongly affected systolic BP levels in men, which may had weakened the association with HRV. In Chinese population, a study showed that reduced HRV and HRT were present in hypertensive patients, particularly in hypertensive patients with uncontrolled BP.

HRV can be used to evaluate cardiac autonomic activity. It shows us the oscillation of heart rate which reflect the sympathetic and vagal function that regulates the heart rate response to any stimuli. HRV can be used to evaluate cardiac autonomic activity. It shows us the oscillation of heart rate which reflect the sympathetic and vagal function that regulates the heart rate response to any stimuli. Apart from external stimuli, HRV is also affected by internal stimuli, including circadian rhythms, core body temperature, metabolism, the sleep cycle, and the renin-angiotensin system. Using 24-hour HRV recordings is the "gold standard" of clinical HRV assessment because it provides greater predictive power than short-term measurements. Deviation of HRV from the normal range is associated with various cardiovascular diseases. The 24-hour recording of SDNN is the "gold standard" of clinical HRV assessment because it provides greater predictive power than short-term measurements.

### Table 4
Multivariate logistic regression for risk of hypertension

| HRV parameters | Uncontrolled HTN (N = 34) | Controlled HTN (N = 18) | Exp (B) | 95% CI lower limit | 95% CI upper limit |
|----------------|---------------------------|-------------------------|---------|--------------------|--------------------|
| Age            | 0.042                     | 0.016                   | 6.478   | .011               | 1.043              | 1.010              | 1.077              |
| Amiodaron use  | -1.860                    | 0.770                   | 5.845   | .016               | 0.156              | 0.034              | 0.703              |
| ACE-i/ARB use  | 1.613                     | 0.507                   | 10.111  | .001               | 5.016              | 1.856              | 13.552             |
| SDANN          | -0.018                    | 0.007                   | 6.638   | .010               | 0.982              | 0.969              | 0.996              |
| ASDNN          | 0.070                     | 0.026                   | 7.082   | .008               | 1.073              | 1.019              | 1.130              |
| rMSSD          | -0.048                    | 0.019                   | 6.210   | .013               | 0.953              | 0.917              | 0.990              |
| LF             | -0.093                    | 0.044                   | 4.415   | .036               | 0.911              | 0.835              | 0.994              |

### Table 5
Comparison of component values of heart rate variability parameters in controlled and uncontrolled blood pressure in hypertensive group

| HRV parameters | Uncontrolled HTN (N = 34) | Controlled HTN (N = 18) | P      |
|----------------|---------------------------|-------------------------|--------|
| Time domain:  |                           |                         |        |
| mean NN (ms)  | 754.50 (719.00-853.00)    | 722.50 (666.00-925.00)  | .617   |
| SDNN (ms)     | 105.00 (89.00-131.00)     | 128.50 (99.00-197.00)   | .043   |
| SDANN (ms)    | 98.50 (76.00-117.00)      | 125.00 (91.00-181.00)   | .041   |
| ASDNN (ms)    | 42.50 (34.00-49.00)       | 61.50 (38.00-72.00)     | .029   |
| rMSSD (ms)    | 25.00 (17.00-32.00)       | 30.50 (19.00-43.00)     | .248   |
| pNN50 (%)     | 19.00 (8.00-87.00)        | 75.50 (23.00-122.00)    | .294   |
| BB50 (beats)  | 3340.50 (1045.00-8406.00) | 4002.00 (1920.00-6561.00) | .729   |

### Frequency domain:

| HRV parameters | Uncontrolled HTN (N = 34) | Controlled HTN (N = 18) | P      |
|----------------|---------------------------|-------------------------|--------|
| VLF (ms)      | 22.72 (18.57-26.15)       | 35.99 (20.03-45.60)     | .020   |
| LF (ms)       | 13.89 (11.06-18.54)       | 24.09 (14.94-33.82)     | .006   |
| HF (ms)       | 8.72 (6.11-13.46)         | 12.88 (8.82-16.46)      | .034   |
| LF/HF ratio   | 1.59 (1.19-2.03)          | 1.79 (1.53-2.44)        | .181   |

Note: Data are presented as median (IQR).

Abbreviations: ASDNN, mean of five-minute standard deviations of intervals; BB50, count of intervals that are more than 50 ms different from the previous interval; HTN, hypertension; HF, high-frequency power; HTN, hypertension; LF, low-frequency power; mean NN, average of all intervals between normal beats excluding ectopy or noise intervals; pNN50, percentage of intervals that are more than 50 ms different from the previous interval; rMSSD, root mean square of the difference of successive R-R intervals; SDANN, standard deviation of five-minute mean R-R interval; SDNN, standard deviation of intervals of all normal beat.
The SDNN value below 50 ms, 50-100, and above 100 are classified as unhealthy, compromised health, and healthy, respectively.16

Essential hypertension results from an increase in systemic vascular resistance, which is greatly provoked by enhanced activity of sympathetic nervous system. Baroreceptor resetting, norepinephrine spillover, increased angiotensin II level in circulation, and local factors like endothelin lead to sympathetic hyperactivity. This sympathetic hyperactivity may ultimately induce sympathovagal imbalance and decreased HRV in hypertensive patients.17,18

Some studies reported the effect of BP medication, including beta-blocker, ACE inhibitor, ARB, and diuretic to HRV. Beta-blockers users had equal or greater HRV than non-users, whereas those using diuretics or ACE inhibitors had a lower HRV.14 Captopril medication increased HRV expressed as total power and LF power in the frequency domain.19 Anti-arrhythmic drug amiodarone also affected HRV. Amiodarone administration showed a reduction of pNN50 and rMSSD.20 In this study, we performed multivariate regression to confounding factors, including anti-arrhythmic and blood pressure medication use. It showed a significant association between several HRV parameters and hypertension, particularly in hypertensive patients with uncontrolled BP. There was considerable effect modification by antihypertensive medication use, with stronger associations among individuals not using antihypertensive medications.

### TABLE 6  Multivariate logistic regression for risk of uncontrolled blood pressure in hypertensive group

| Source of the Curve | B     | S.E  | Wald  | P-value | Exp (B) | 95% CI lower limit | 95% CI upper limit |
|---------------------|-------|------|-------|---------|---------|--------------------|--------------------|
| Sex (male)          | −1.812| 0.893| 4.122 | .042    | 0.163   | 0.028              | 0.939              |
| BMI                 | 0.330 | 0.133| 6.112 | .013    | 1.391   | 1.071              | 1.807              |
| SDNN                | −0.095| 0.039| 5.838 | .016    | 0.909   | 0.842              | 0.982              |
| SDANN               | 0.056 | 0.028| 4.041 | .044    | 1.058   | 1.001              | 1.117              |
| rMSSD               | 0.211 | 0.096| 4.836 | .028    | 1.235   | 1.023              | 1.490              |
| HF                  | −0.300| 0.165| 3.323 | .068    | 0.741   | 0.537              | 1.023              |

Abbreviations: BMI, body mass index; HF, high-frequency power; rMSSD, root mean square of the difference of successive R-R intervals; SDANN, standard deviation of five-minute mean R-R interval; SDNN, standard deviation of intervals of all normal beat.

### FIGURE 2  Receiver operator characteristic (ROC) curve for the prediction of uncontrolled blood pressure in hypertensive group by SDNN, SDANN, ASDNN, VLF, LF and HF. The 95% CIs of the area under the ROC curve are presented in Table S2

In this study, we performed multivariate regression to confounding factors, including anti-arrhythmic and blood pressure medication use. It showed a significant association between several HRV parameters and hypertension, particularly in hypertensive patients with uncontrolled BP. There was considerable effect modification by antihypertensive medication use, with stronger associations among individuals not using antihypertensive medications.

#### 4.1  Clinical implication and recommendation

Monitoring HRV, which reflects the cardiac sympathetic and vagal function, can be useful to evaluate the autonomic nervous function status of hypertensive patients and optimize therapeutic efficacy to improve autonomic nervous function balance. Moreover, this study suggests that a prospective study is needed to find the casual relationship between decreased autonomic nervous function and new-onset HTN or cardiovascular disease, especially in Asian population. HRV might also be able to predict the future risk of HTN at an earlier stage and prognosis during treatment.
4.2 Study limitation

Several limitations of this study should be considered. First, we could not confirm the presence of a causal relationship between cardiac autonomic nervous impairment and HTN due to the cross-sectional design of the study with a relatively small sample size. Second, age of patients in the HTN group was significantly higher than those in the non-HTN group. HRV parameters in an elderly population are usually lower than those of a younger population; therefore, this result is possibly biased in terms of age. After adjusting for age as one of risk factors of HTN in multivariate model, we found that HRV is an independent risk factor for HTN. Third, we could not exclude the effects of medication that affect autonomic cardiac function. Fourth, most subjects recruited in this study were patients with arrhythmia indicated for Holter study. This might cause population bias, and the result of this study only represent a population of patient with arrhythmia and HTN.

5 CONCLUSION

Our study showed that cardiac autonomic nervous impairment, as demonstrated by reduced HRV, is significantly associated with HTN. Decreased HRV was also significantly associated with uncontrolled blood pressure in hypertensive patients.

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE

Dr Soetomo General Hospital conferred ethical clearance for this study (Ref: 1822/KEPK/II/2020; February 20, 2020). A written informed consent was obtained from all patients.

ACKNOWLEDGEMENTS

The authors thank Muhammad Aditya, MD for doing the statistical analysis for this study.

CONFLICT OF INTEREST

Authors declare no conflict of interests for this article.

ORCID

Rerdin Julario  https://orcid.org/0000-0002-7201-2460
Eka Prasetya Budi Mulia  https://orcid.org/0000-0002-2681-7743
Ivana Purnama Dewi  https://orcid.org/0000-0002-1602-3384

REFERENCES

1. Fisher NDL, Curfman G. Hypertension — a public health challenge of global proportions. JAMA. 2018;320(17):1757–9.
2. Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, et al. Hypertension in older adults: assessment, management, and challenges. Clin Cardiol. 2020;43(2):99–107.
3. Carthy ER. Autonomic dysfunction in essential hypertension: a systematic review. Ann Med Surg. 2014;3(1):2–7.
4. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804–14.
5. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2016;116(6):976–90.
6. Huikuri HV, Stein PK. Heart rate variability in risk stratification of cardiac patients. Prog Cardiovasc Dis. 2013;56(2):153–9.
7. Yu Y, Xu Y, Zhang M, Wang Y, Zou W, Gu Y. Value of assessing autonomic nervous function by heart rate variability and heart rate turbulence in hypertensive patients. Int J Hypertens. 2018;2018:4067601.
8. Malik M, Camm AJ, Bigger TJ, Breithardt G, Cerutti S, Cohen RJ, et al. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation. 1996;93(5):1043–65.
9. Mori H, Saito I, Eguchi E, Maruyama K, Kato T, Tanigawa T. Heart rate variability and blood pressure among Japanese men and women: a community-based cross-sectional study. Hypertens Res. 2014;37(8):779–84.
10. Natarajan N, Balakrishnan AK, Ukkirapandian K. A study on analysis of heart rate variability in hypertensive individuals. Int J Biomed Adv Res. 2014;5(2):109.
11. Saito I, Takata Y, Maruyama K, Eguchi E, Kato T, Shirahama R, et al. Association between heart rate variability and home blood pressure: the toon health study. Am J Hypertens. 2018;31(10):1120–6.
12. Koichubekov BK, Sorokina MA, Laryushina YM, Turgunova LG, Korschukov IV. Nonlinear analyses of heart rate variability in hypertension. Ann Cardiol Angeiol (Paris). 2018;67(3):174–9.
13. Routledge FS, Campbell TS, McFetridge-Durdle JA, Bacon SL. Improvements in heart rate variability with exercise therapy. Can J Cardiol. 2010;26(6):303–12.
14. Schroeder EB, Liao D, Chambless LE, Prineas RJ, Evans GW, Heiss G. Hypertension, blood pressure, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Hypertension. 2003;42(6):1106–11.
15. Lombardi F, Stein PK. Origin of heart rate variability and turbulence: an appraisal of autonomic modulation of cardiovascular function. Front Physiol. 2011;2:95.
16. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health. 2017;5:258.
17. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976–90.
18. Sena CM, Leandro A, Azul L, Seica R, Perry G. Vascular oxidative stress: Impact and therapeutic approaches. Front Physiol. 2018;9:1668.
19. Jansson K, Östlund R, Nylander E, Dahlström U, Hagerman I, Karlberg K-E, et al. The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy. Clin Cardiol. 1999;22(6):397–402.
20. Rohde LEP, Polanczyk CA, Moraes RS, Ferlin E, Ribeiro JP. Effect of partial arrhythmia suppression with amiodarone on heart rate variability of patients with congestive heart failure. Am Heart J. 1998;136(1):31–6.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.